Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease

Jae Myeong Kang, Sang Yoon Lee, Seongho Seo, Hye Jin Jeong, Sung Ho Woo, Hyon Lee, Yeong Bae Lee, Byeong Kil Yeon, Dong Hoon Shin, Kee Hyung Park, Hyejin Kang, Nobuyuki Okamura, Shozo Furumoto, Kazuhiko Yanai, Victor L. Villemagne, Jun Kyung Seong, Duk L. Na, Tatsuo Ido, Jaelim Cho, Kyoung Min Lee & 1 others Young Noh

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

This study aims to evaluate the clinical validity of [18F]THK5351 positron emission tomography (PET) for the assessment of disease progression and symptoms in Alzheimer's disease (AD). Fifty-one patients with AD dementia, 30 patients with amnestic mild cognitive impairment (aMCI), and 43 controls with normal cognition (NC) were included. All subjects underwent [18F]THK5351 PET, 3.0-T magnetic resonance imaging, and detailed neuropsychological tests. Regions of interest and voxel-based statistical analyses were performed. In patients with AD dementia, [18F]THK5351 retention was greater in most association cortices as well as the limbic area compared to NC or aMCI participants. Patients with aMCI also showed higher THK5351 retention in those areas compared to NC. [18F]THK5351 retention significantly correlated with neuropsychological test results. Negative correlations between [18F]THK5351 and [18F] fluorodeoxyglucose were observed in AD dementia and aMCI groups. Mirror images of [18F]THK5351 retention and glucose hypometabolism in [18F] fluorodeoxyglucose were noticeable in the focal variants of AD. [18F]THK5351 PET reflects disease severity and symptoms in AD. Our results suggest [18F]THK5351 is reflective of tau-related AD pathology.

Original languageEnglish
Pages (from-to)210-219
Number of pages10
JournalNeurobiology of Aging
Volume59
DOIs
Publication statusPublished - 2017 Nov 1

Fingerprint

Positron-Emission Tomography
Alzheimer Disease
Glucose
Cognition
Neuropsychological Tests
Fluorodeoxyglucose F18
THK5351
Disease Progression
Magnetic Resonance Imaging
Pathology
Cognitive Dysfunction

Keywords

  • Alzheimer's disease
  • Neurofibrillary tangles
  • Positron emission tomography
  • Tau
  • THK

ASJC Scopus subject areas

  • Neuroscience(all)
  • Ageing
  • Developmental Biology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease. / Kang, Jae Myeong; Lee, Sang Yoon; Seo, Seongho; Jeong, Hye Jin; Woo, Sung Ho; Lee, Hyon; Lee, Yeong Bae; Yeon, Byeong Kil; Shin, Dong Hoon; Park, Kee Hyung; Kang, Hyejin; Okamura, Nobuyuki; Furumoto, Shozo; Yanai, Kazuhiko; Villemagne, Victor L.; Seong, Jun Kyung; Na, Duk L.; Ido, Tatsuo; Cho, Jaelim; Lee, Kyoung Min; Noh, Young.

In: Neurobiology of Aging, Vol. 59, 01.11.2017, p. 210-219.

Research output: Contribution to journalArticle

Kang, JM, Lee, SY, Seo, S, Jeong, HJ, Woo, SH, Lee, H, Lee, YB, Yeon, BK, Shin, DH, Park, KH, Kang, H, Okamura, N, Furumoto, S, Yanai, K, Villemagne, VL, Seong, JK, Na, DL, Ido, T, Cho, J, Lee, KM & Noh, Y 2017, 'Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease', Neurobiology of Aging, vol. 59, pp. 210-219. https://doi.org/10.1016/j.neurobiolaging.2017.08.008
Kang, Jae Myeong ; Lee, Sang Yoon ; Seo, Seongho ; Jeong, Hye Jin ; Woo, Sung Ho ; Lee, Hyon ; Lee, Yeong Bae ; Yeon, Byeong Kil ; Shin, Dong Hoon ; Park, Kee Hyung ; Kang, Hyejin ; Okamura, Nobuyuki ; Furumoto, Shozo ; Yanai, Kazuhiko ; Villemagne, Victor L. ; Seong, Jun Kyung ; Na, Duk L. ; Ido, Tatsuo ; Cho, Jaelim ; Lee, Kyoung Min ; Noh, Young. / Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease. In: Neurobiology of Aging. 2017 ; Vol. 59. pp. 210-219.
@article{7046e073d8984fe48cc03ba7bc818d05,
title = "Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease",
abstract = "This study aims to evaluate the clinical validity of [18F]THK5351 positron emission tomography (PET) for the assessment of disease progression and symptoms in Alzheimer's disease (AD). Fifty-one patients with AD dementia, 30 patients with amnestic mild cognitive impairment (aMCI), and 43 controls with normal cognition (NC) were included. All subjects underwent [18F]THK5351 PET, 3.0-T magnetic resonance imaging, and detailed neuropsychological tests. Regions of interest and voxel-based statistical analyses were performed. In patients with AD dementia, [18F]THK5351 retention was greater in most association cortices as well as the limbic area compared to NC or aMCI participants. Patients with aMCI also showed higher THK5351 retention in those areas compared to NC. [18F]THK5351 retention significantly correlated with neuropsychological test results. Negative correlations between [18F]THK5351 and [18F] fluorodeoxyglucose were observed in AD dementia and aMCI groups. Mirror images of [18F]THK5351 retention and glucose hypometabolism in [18F] fluorodeoxyglucose were noticeable in the focal variants of AD. [18F]THK5351 PET reflects disease severity and symptoms in AD. Our results suggest [18F]THK5351 is reflective of tau-related AD pathology.",
keywords = "Alzheimer's disease, Neurofibrillary tangles, Positron emission tomography, Tau, THK",
author = "Kang, {Jae Myeong} and Lee, {Sang Yoon} and Seongho Seo and Jeong, {Hye Jin} and Woo, {Sung Ho} and Hyon Lee and Lee, {Yeong Bae} and Yeon, {Byeong Kil} and Shin, {Dong Hoon} and Park, {Kee Hyung} and Hyejin Kang and Nobuyuki Okamura and Shozo Furumoto and Kazuhiko Yanai and Villemagne, {Victor L.} and Seong, {Jun Kyung} and Na, {Duk L.} and Tatsuo Ido and Jaelim Cho and Lee, {Kyoung Min} and Young Noh",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.neurobiolaging.2017.08.008",
language = "English",
volume = "59",
pages = "210--219",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease

AU - Kang, Jae Myeong

AU - Lee, Sang Yoon

AU - Seo, Seongho

AU - Jeong, Hye Jin

AU - Woo, Sung Ho

AU - Lee, Hyon

AU - Lee, Yeong Bae

AU - Yeon, Byeong Kil

AU - Shin, Dong Hoon

AU - Park, Kee Hyung

AU - Kang, Hyejin

AU - Okamura, Nobuyuki

AU - Furumoto, Shozo

AU - Yanai, Kazuhiko

AU - Villemagne, Victor L.

AU - Seong, Jun Kyung

AU - Na, Duk L.

AU - Ido, Tatsuo

AU - Cho, Jaelim

AU - Lee, Kyoung Min

AU - Noh, Young

PY - 2017/11/1

Y1 - 2017/11/1

N2 - This study aims to evaluate the clinical validity of [18F]THK5351 positron emission tomography (PET) for the assessment of disease progression and symptoms in Alzheimer's disease (AD). Fifty-one patients with AD dementia, 30 patients with amnestic mild cognitive impairment (aMCI), and 43 controls with normal cognition (NC) were included. All subjects underwent [18F]THK5351 PET, 3.0-T magnetic resonance imaging, and detailed neuropsychological tests. Regions of interest and voxel-based statistical analyses were performed. In patients with AD dementia, [18F]THK5351 retention was greater in most association cortices as well as the limbic area compared to NC or aMCI participants. Patients with aMCI also showed higher THK5351 retention in those areas compared to NC. [18F]THK5351 retention significantly correlated with neuropsychological test results. Negative correlations between [18F]THK5351 and [18F] fluorodeoxyglucose were observed in AD dementia and aMCI groups. Mirror images of [18F]THK5351 retention and glucose hypometabolism in [18F] fluorodeoxyglucose were noticeable in the focal variants of AD. [18F]THK5351 PET reflects disease severity and symptoms in AD. Our results suggest [18F]THK5351 is reflective of tau-related AD pathology.

AB - This study aims to evaluate the clinical validity of [18F]THK5351 positron emission tomography (PET) for the assessment of disease progression and symptoms in Alzheimer's disease (AD). Fifty-one patients with AD dementia, 30 patients with amnestic mild cognitive impairment (aMCI), and 43 controls with normal cognition (NC) were included. All subjects underwent [18F]THK5351 PET, 3.0-T magnetic resonance imaging, and detailed neuropsychological tests. Regions of interest and voxel-based statistical analyses were performed. In patients with AD dementia, [18F]THK5351 retention was greater in most association cortices as well as the limbic area compared to NC or aMCI participants. Patients with aMCI also showed higher THK5351 retention in those areas compared to NC. [18F]THK5351 retention significantly correlated with neuropsychological test results. Negative correlations between [18F]THK5351 and [18F] fluorodeoxyglucose were observed in AD dementia and aMCI groups. Mirror images of [18F]THK5351 retention and glucose hypometabolism in [18F] fluorodeoxyglucose were noticeable in the focal variants of AD. [18F]THK5351 PET reflects disease severity and symptoms in AD. Our results suggest [18F]THK5351 is reflective of tau-related AD pathology.

KW - Alzheimer's disease

KW - Neurofibrillary tangles

KW - Positron emission tomography

KW - Tau

KW - THK

UR - http://www.scopus.com/inward/record.url?scp=85029616089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029616089&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2017.08.008

DO - 10.1016/j.neurobiolaging.2017.08.008

M3 - Article

VL - 59

SP - 210

EP - 219

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

ER -